LEXINGTON, Mass., March 8, 2022 /PRNewswire/ --
LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a
clinical-stage genetic medicine company, today announced that
president and chief executive officer, Frederic Chereau, will participate in a fireside
chat during the Barclays Global Healthcare Conference on
March 15, 2022, at 3:20 p.m. ET.
A live webcast of the presentation will be made available on the
Investors section of the Company's website at
https://investor.logicbio.com. The webcast replay will be available
for approximately 30 days.
About LogicBio Therapeutics
LogicBio® Therapeutics is a clinical-stage genetic
medicine company pioneering genome editing and gene delivery
platforms to address rare and serious diseases from infancy through
adulthood. The company's genome editing platform, GeneRide™, is a
new approach to precise gene insertion harnessing a cell's natural
DNA repair process potentially leading to durable therapeutic
protein expression levels. The company's gene delivery platform,
sAAVy™, is an adeno-associated virus (AAV) capsid engineering
platform designed to optimize gene delivery for treatments in a
broad range of indications and tissues. The company is based in
Lexington, MA. For more
information, visit www.logicbio.com, which does not form a part of
this release.
Investor Contacts:
Stephen Jasper
Gilmartin Group
858-525-2047
stephen@gilmartinir.com
Media Contacts:
Adam
Daley
Berry & Company Public Relations
W:212-253-8881
C: 614-580-2048
adaley@berrypr.com
View original
content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-barclays-global-healthcare-conference-301498370.html
SOURCE LogicBio Therapeutics
